Literature DB >> 25734416

An overview of immunosuppression in solid organ transplantation.

Cher Enderby1, Cesar A Keller.   

Abstract

Significant advancements in solid organ transplantation immunosuppressive medications and regimens have resulted in improved outcomes over the years. A multidrug approach involving medications with different mechanisms of action is commonly used. Induction therapy can involve the use of antibody agents or higher doses of medications used for maintenance therapy. A calcineurin inhibitor, an antiproliferative agent, and a corticosteroid commonly serve as the initial triple medication regimen. Due to the potential for nephrotoxicity with the use of calcineurin inhibitors and chronic conditions with the prolonged use of corticosteroids, various withdrawal strategies are used in practice. Antimicrobial agents are prescribed to provide prophylaxis against certain viral, fungal, and bacterial infections. Other concomitant medications in the regimens for patients who have undergone transplantation vary depending on patient-specific factors and conditions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25734416

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  26 in total

1.  Redirecting reproductive immunology research toward pregnancy as a period of temporary immune tolerance.

Authors:  Norbert Gleicher; Vitaly A Kushnir; David H Barad
Journal:  J Assist Reprod Genet       Date:  2017-02-10       Impact factor: 3.412

2.  In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Georgia Antoniadi; Nikolaos Antoniadis; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2017-05-15       Impact factor: 2.370

Review 3.  Prevention of chronic rejection after lung transplantation.

Authors:  Anke Van Herck; Stijn E Verleden; Bart M Vanaudenaerde; Geert M Verleden; Robin Vos
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

4.  Induction Therapy and Therapeutic Antibodies.

Authors:  Andriana Nikolova; Jignesh K Patel
Journal:  Handb Exp Pharmacol       Date:  2022

5.  Mapping Transplant Arteriosclerosis Cell-by-Cell: A Path to New Immune Insights.

Authors:  Dawn M Fernandez; Chiara Giannarelli
Journal:  Circ Res       Date:  2020-09-24       Impact factor: 17.367

6.  Nanotechnological Approaches to Immunosuppression and Tolerance Induction.

Authors:  Kunal Patel; Carl Atkinson; Danh Tran; Satish N Nadig
Journal:  Curr Transplant Rep       Date:  2017-04-17

7.  Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016.

Authors:  Elizabeth B Gray; Ricardo M La Hoz; Jaime S Green; Holenarasipur R Vikram; Theresa Benedict; Hilda Rivera; Susan P Montgomery
Journal:  Transpl Infect Dis       Date:  2018-10-02       Impact factor: 2.228

Review 8.  Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.

Authors:  Jilu Zhang; Alan Hodges; Shu-Hsia Chen; Ping-Ying Pan
Journal:  Cell Immunol       Date:  2021-02-04       Impact factor: 4.868

9.  Presentation and outcomes of chronic rhinosinusitis following liver and kidney transplant.

Authors:  Aviv Spillinger; Christopher M Low; Byron M Smith; Janalee K Stokken; Erin K O'Brien; Garret Choby
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-06-04

10.  Tacrolimus Dose-Conversion Ratios Based on Switching of Formulations for Patients with Solid Organ Transplants.

Authors:  Wen-Yuan Johnson Kuan; Nathalie Châteauvert; Vincent Leclerc; Benoît Drolet
Journal:  Can J Hosp Pharm       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.